Navigation Links
Loic Maurel Joins Exonhit Therapeutics to Become CEO
Date:6/4/2008

eloping its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk Factors) of the Document de Base available on ExonHit Therapeutics' website (http://www.exonhit.com), that may cause actual results, performance or events to differ materially from those anticipated in the summary information.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French langu
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. David M. Stout Joins NanoBio Corporations Board of Directors
2. Dan Renick, RPh, Joins The Hobart Group as Managing Partner
3. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
4. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
5. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
6. Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
7. Basil Zimmo Joins Finesse Solutions as Vice-President of Software
8. Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Harvey Morgan Joins CryoLife Board of Directors
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 Shimadzu Scientific ... and present on LCMS and marijuana analysis at the ... March 8 to 12 at the Ernest N. Morial ... can stop by booth 3121 to discuss laboratory challenges ... company’s innovative, proven products help save time, money and ...
(Date:3/2/2015)... YORK and VANCOUVER, British Columbia ... Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical ... cannabinoid based therapies, today announced that Craig ... company overview during a live webcast at VirtualInvestorConferences.com. ... ET LINK:   http://VirtualInvestorConferences.com > click the ...
(Date:3/2/2015)... SANTA BARBARA, Calif. , March 2, 2015 ... a biotechnology company developing therapies for autoimmune and ... Trademark Office (USPTO) has issued an important new ... immune system function through the targeting of CLIP. ... the targeted peptide technology underlying VG Life Sciences, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3InMed Pharmaceuticals to Present Investor Webcast March 5 2VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Inc. (NYSE: MYL ),today announced that Mylan Pharmaceuticals ... Drug Administration (FDA) for its,Abbreviated New Drug Application (ANDA) ... 200 mg., Lamotrigine Tablets are the generic version ... $1.97 billion,for the 12 months ending Sept. 30, 2007., ...
... venture syndicate invests to advance expanding pipeline of products to ... ... Fovea Pharmaceuticals SA, a,biopharmaceutical company developing novel therapeutics for the ... in a,Series B financing from a strong, international syndicate of ...
... is,GlaxoSmithKline,s (NYSE: GSK ) response to ... Evaluative Sciences (ICES) titled,"Thiazolidinediones and Cardiovascular Outcomes ... that the ICES retrospective analysis of the ... and generates misleading,conclusions regarding acute myocardial infarction ...
Cached Biology Technology:Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 2GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 3GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 5
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... YORK and POINT ROBERTS, Washington ... news source covering leading sectors including technology and tech stocks, ... Privacy marketplace featuring master pickpocket and security consultant Apollo ... is stolen and talks about the Wocket™ biometric smart wallet, ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... are replaced through cell division. Researchers at Karolinska Institutet ... genetic information remains intact despite this continuous exchange of ... of the scientific journal Molecular Cell. , An adult ... which die and are replaced by cell division every ...
... the second major form of dementia. Under the ... Flanders Interuniversity Institute for Biotechnology (VIB) affiliated to ... the progranulin growth factor plays an important biological ... dementia. Because progranulin is known primarily for its ...
... scientists at Indiana University Bloomington report biochemical machinery ... weakest of scents. Even when ovary extracts were ... their mark. , A video demonstrating sperm chemotaxis ... can be downloaded at http://www.iuinfo.indiana.edu/bem/media_relations/movie.chemotaxis.mpg (Credit: Stephen ...
Cached Biology News:A protein complex that untangles DNA 2Researchers find cause of frontotemporal dementia 2Even when faint, ovary scent draws sperm cells 2